HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- (4- (1,2,3,4- tetrahydroxybutyl)- 1H- imidazol- 2- yl)ethanone oxime

inhibits sphingosine-1-phosphate lyase; structure in first source

Also Known As:

LX 2931; LX-2931; LX2931

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - 1-(4-(1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime: 5
Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Oximes: 1292
      - 1-(4-(1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime: 5

Experts

1.	Oravecz, Tamas: 2 articles (11/2016 - 12/2010)
2.	Auclair, Christian: 1 article (03/2022)
3.	Ives, Annette: 1 article (03/2022)
4.	Karam, Manale: 1 article (03/2022)
5.	Burkhart, Christoph: 1 article (01/2019)
6.	Haberhauer, Gebhard: 1 article (01/2019)
7.	Heusch, Gerd: 1 article (01/2019)
8.	Keul, Petra: 1 article (01/2019)
9.	Levkau, Bodo: 1 article (01/2019)
10.	Manthe, Kristina: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 03/03/2022 - "In pancreatic adenocarcinoma PDX models, oral administration of an S1P lyase inhibitor (LX2931) significantly increased plasma S1P levels, decreased tumor expression of the hypoxia marker (CA IX), and enhanced chemotherapy efficacy when combined with gemcitabine treatment. "
2.	Hypoxia (Hypoxemia) 03/03/2022 - "In pancreatic adenocarcinoma PDX models, oral administration of an S1P lyase inhibitor (LX2931) significantly increased plasma S1P levels, decreased tumor expression of the hypoxia marker (CA IX), and enhanced chemotherapy efficacy when combined with gemcitabine treatment. "
3.	Adenocarcinoma 03/03/2022 - "In pancreatic adenocarcinoma PDX models, oral administration of an S1P lyase inhibitor (LX2931) significantly increased plasma S1P levels, decreased tumor expression of the hypoxia marker (CA IX), and enhanced chemotherapy efficacy when combined with gemcitabine treatment. "
4.	Inflammation (Inflammations) 07/08/2022 - "Perinatal delivery of the SPL inhibitor LX2931 to mdx mice augmented muscle S1P and SC numbers, reduced leukocytes in peripheral blood and skeletal muscle, and attenuated muscle inflammation and degeneration. " 11/01/2016 - "LX2931 does not prevent transient inflammation or goblet cell hyperplasia after challenge, but it reduces MUC5AC and proinflammatory cytokine levels toward normal values. "
5.	Rheumatoid Arthritis 01/01/2019 - "We compared its efficacy to LX2931, a novel S1P lyase inhibitor currently tested in rheumatoid arthritis. " 12/23/2010 - "Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)."

Related Drugs and Biologics

1.	Lyases
2.	Gemcitabine
3.	Cytokines
4.	Oximes
5.	1- (2- (isoxazol- 3- yl)- 1H- imidazol- 4- yl)butane- 1,2,3,4- tetraol
6.	sphingosine 1-phosphate (sphingosine-1-phosphate)
7.	sphingosine 1-phosphate lyase (aldolase)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration